The Cancer Letter

Inside information on cancer research and drug development

Vol.
30
No.
16
April 16, 2004Apr 16, 2004
Free
DOWNLOAD THE PDF

NCI disclosure of walk-out by Data and Safety Monitoring Board of the National Lung Screening Trial may be harmful, improper, experts say.

NCI Cancer Bulletin publicized board’s resignation over liability concerns.

NCI reassigns project officer John Gohagan.

Also in this 8-page issue: NCI, FDA open Web site for adverse event reporting.

Kansas Cancer Institute gets $15 million pledge, is renamed, and hires a new director in effort to win NCI center grant.

Funding opportunities listed.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account